This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           June 25, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

FDA staff question benefit of ovarian cancer drug olaparib
Reuters
AstraZeneca Plc's experimental ovarian cancer drug, olaparib, showed an 83 percent reduction in the risk of disease progression, but a U.S. Food and Drug Administration staff review has questioned whether the result could be reproduced. The company's shares fell 1.8 percent to 43.89 pounds on the London Stock Exchange.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




GENETICS


Treacherous immune genes can cause cancer after viral infection
Oncology Nurse Advisor
New research published in Cell Reports showed for the first time that genes from the 'APOBEC' family, which help to fight off viral infection, actually cause mutations that lead to HPV-associated cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


OVARIAN CANCER


Amgen drug improves ovarian cancer treatment, lowers recurrence
Science 2.0
Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix report in Lancet Oncology that a new treatment for ovarian cancer can improve response rates and prolong the time until cancers recur. Trebananib is a first-in-class peptide-Fc fusion protein that targets angiogenesis by inhibiting the binding of both angiopoietin 1 and 2 to the Tie2 receptor.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


ENDOMETRIAL CANCER


No link found between soy, endometrial cancer risk
BJOG: An International Journal of Obstetrics and Gynaecology
Researchers have found no evidence of a protective association between soy food and endometrial cancer risk, says a study published in BJOG: An International Journal of Obstetrics and Gynaecology. Soy foods are an almost exclusive dietary source of isoflavones, a plant-derived estrogen. Some studies have highlighted their potential cancer protective properties; however, research looking at the link to endometrial cancer has been inconsistent.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  FEATURED COMPANIES
Exceptional Care, Close to Home

21st Century Oncology – the nation’s largest cancer treatment network and global leader in cancer care – providing integrated clinical teams treating patients collaboratively to improve outcomes.
MORE
Lantheus Proven Success
Discovering, developing and marketing innovative medical imaging agents provides a strong platform from which to bring forward new breakthrough tools for the diagnosis and management of disease. MORE


PREVENTION


Single-agent paclitaxel fails in noninferiority trial for primary breast cancer
The Oncology Report
Single-agent paclitaxel has failed to demonstrate noninferiority, compared with doxorubicin and cyclophosphamide in patients with early-stage, operable breast cancer, although it did show significantly less toxicity. Published in the Journal of Clinical Oncology, the trial in 3,871 women, followed for a median of 6.1 years and treated with four or six cycles of each treatment, recorded a hazard ratio (HR) for relapse-free survival of 1.26, favoring the combination of doxorubicin and cyclophosphamide, with an upper-bound confidence interval of 1.48, which exceeded the upper confidence bound of 1.3.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




BREAST CANCER


Prolonged sitting ups risk of developing certain cancers
HealthDay News via Healthcare Professionals Network
Prolonged television (TV) viewing and other sedentary behaviors are associated with increased risks of some cancers, according to research published online June 16 in the Journal of the National Cancer Institute. Daniela Schmid, PhD, and Michael F. Leitzmann, MD, DrPH, of the University of Regensburg in Germany, performed a meta-analysis using data from 43 observational studies involving 68,936 cancer cases. The authors sought to assess the association between sedentary behaviors and cancer risk.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


'Silently suffering': Breast cancer before 40 and sexuality
Medscape (Free login required)
Treatment-associated premature ovarian failure is an important factor in sexual dysfunction in young breast cancer survivors, according to new research. Their study, which is the largest analysis of sexual functioning during the post-treatment period in young women with breast cancer, was published online May 28 in Cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

June 18, 2014
June 11, 2014
June 4, 2014
May 28, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063